trial

Study on the Efficacy and Safety of QLM1016 in Schizophrenia

NCTId NCT06799559
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Not Yet Recruiting
Enrollment 402 (estimated)
Sponsored by Qilu Pharmaceutical Co., Ltd.
Primary completion 2026-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Not Yet Recruiting
Enrollment
402 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2025-05
Primary completion
2026-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
3-6mg QLM1016Aripiprazole

Sponsors

Qilu Pharmaceutical Co., Ltd.Lead Sponsor

Sites

0 total

Linked catalysts

1
Study on the Efficacy and Safety of QLM1016 in Schizophrenia — primary completion2026-07

Facts & assertions

4 sourced
Enrollment
402
Phase
PHASE3
Primary Completion Date
2026-07
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
3-6mg QLM1016
drug
Aripiprazole
drug
lead_sponsor
Qilu Pharmaceutical Co., Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication